Geode Capital Management LLC Sells 44,869 Shares of Catalent, Inc. (NYSE:CTLT)

Geode Capital Management LLC lessened its stake in shares of Catalent, Inc. (NYSE:CTLT) by 1.0% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 4,265,795 shares of the company’s stock after selling 44,869 shares during the quarter. Geode Capital Management LLC’s holdings in Catalent were worth $257,498,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of CTLT. Nomura Asset Management Co. Ltd. raised its holdings in Catalent by 1.4% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 53,011 shares of the company’s stock valued at $3,211,000 after acquiring an additional 750 shares during the period. National Bank of Canada FI grew its position in shares of Catalent by 300.0% in the third quarter. National Bank of Canada FI now owns 1,460,813 shares of the company’s stock valued at $88,481,000 after purchasing an additional 1,095,578 shares during the last quarter. State Street Corp increased its stake in shares of Catalent by 1.5% during the third quarter. State Street Corp now owns 7,451,135 shares of the company’s stock worth $451,315,000 after purchasing an additional 113,095 shares during the period. Quantinno Capital Management LP lifted its holdings in Catalent by 30.6% during the 3rd quarter. Quantinno Capital Management LP now owns 16,290 shares of the company’s stock worth $987,000 after purchasing an additional 3,817 shares during the last quarter. Finally, Quarry LP bought a new stake in Catalent in the 3rd quarter valued at $4,482,000.

Insider Activity

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the transaction, the insider now owns 36,304 shares of the company’s stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,114 shares of company stock worth $305,931. Insiders own 0.31% of the company’s stock.

Catalent Trading Up 0.0 %

CTLT opened at $63.07 on Friday. The stock has a market capitalization of $11.45 billion, a price-to-earnings ratio of -27.91, a P/E/G ratio of 2.70 and a beta of 1.15. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a twelve month low of $40.29 and a twelve month high of $63.25. The company has a 50-day simple moving average of $60.30 and a 200 day simple moving average of $59.00.

Catalent (NYSE:CTLT) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. During the same quarter in the prior year, the business posted ($0.10) EPS. The business’s revenue was up 4.2% on a year-over-year basis. Analysts predict that Catalent, Inc. will post 0.78 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on CTLT. StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a research report on Tuesday, December 10th. William Blair restated a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 price objective on shares of Catalent in a research note on Tuesday, September 24th. Finally, Baird R W lowered shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.